• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Legal win, buyouts boost Bard’s bottom line

Legal win, buyouts boost Bard’s bottom line

February 3, 2014 By Brian Johnson

A nearly $900 million award from W.L. Gore boosted C.R. Bard’s bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.

Legal wins, buyouts boost Bard's bottom line

C.R. Bard (NYSE:BCR) sowed the fruits of victory from its decades-long patent infringement war with W.L. Gore & Assoc. during the 4th quarter, reporting a massive bottom-line boost from its legal win.

Bard, which last year won a patent infringement decision over stent graft technology, began receiving royalty payments from Gore in October 2013, recording a pre-tax gain of $894.3 million during the 3 months ended Dec. 31, 2013.

Bard also boosted its bottom line with an additional $213.0 million related to the sale of its electrophysiology division to Boston Scientific (NYSE:BSX), which closed during the quarter.

Murray Hill, N.J.-based Bard posted profits of $667.5 million, or $8.28 per share, on sales of $791.3 million. That’s a whopping 420.7% bottom-line gain on sales growth of 3.8% compared with the same perdiod last year. Adjusted to exclude 1-time items, profits were$114.7 million, or $1.42, down some 20.3% compared with Q4 2012.

Investors on Wall Street, hoping for adjusted earnings per share of $1.85, sent BCR shares down 1.1% Jan. 31, to a $129.59 close. The stock was trading at $127.68 per share today as of about 10:20 a.m. today, down 1.5%.

Full-year profits were $689.8 million, or $8.39 per share, on sales of $3.05 billion, for profit growth of 30.1% on sales growth of 3.1%. Adjusted profits were $474.9 million, or $5.78 per share, down 16.0% compared with 2012.

"We are pleased with the results from the first year of our investment and transition plan announced a year ago. We are executing on a strategy with the objective to shift the mix of the portfolio to faster growth through investments in emerging markets and new product categories; and our business development activities are helping to improve the long-term revenue growth profile of the business," chairman & CEO Timothy Ring said in prepared remarks.

Bard CFO Christopher Holland told analysts during a conference call that the company expects adjusted EPS growth of 26%-27%, or $8.20 to $8.27, on constant-currency sales growth of between 6% and 8%, including $130 million to $140 million in payments from Gore.

First-quarter adjusted EPS are pegged at $1.83-$1.87 on sales growth of 6%-7%, Holland said.

We’re forecasting Q1 2014 with adjusted cash EPS between $1.83 and $1.87 per share compared to the prior year at $1.61. We expect Q1 sales growth to be between 6% and 7%, including the first quarterly royalty payment being received from Gore.

Bard also announced a plan to repurchase of up to $500 million of the company’s stock.

Filed Under: Legal News, MassDevice Earnings Roundup, Mergers & Acquisitions, News Well Tagged With: 2013, C.R. Bard, Q4, W.L. Gore & Associates

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy